Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

77.47
Delayed Data
As of Feb 23
 -1.94 / -2.44%
Today’s Change
27.24
Today|||52-Week Range
95.91
+32.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It offers the two protease inhibitors Maviret and the Viekira Pak for the treatment of chronic hepatitis C virus. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Contact Information

Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown Massachusetts 02472
P:(617) 607-0800
Investor Relations:
(781) 235-3060

Employees

Shareholders

Other institutional42.67%
Individual stakeholders35.79%
Mutual fund holders31.57%

Top Executives

Jay R. LulyPresident, Chief Executive Officer & Director
Paul J. MellettCFO, Principal Accounting Officer & SVP-Finance
Yat Sun OrCSO, Senior Vice President-Research & Development
Nathalie AddaChief Medical Officer & Senior Vice President
Nathaniel S. GardinerSenior Vice President & General Counsel